Tagged with

Egypt Mohamed Ali Abd El Azim gives several insights into GSK’s sizeable production footprint in Egypt, how the organisation’s aims dovetail with Egypt’s healthcare transformation, and what makes him proud to work in pharma manufacturing.   Our country is improving and reshaping the healthcare industry and we as GSK have the…

Americas Latin America (LatAm) Area Lead for Astellas Sandra Ramirez outlines the Japanese company’s presence in the region, its efforts to partner with local stakeholders to improve patient access, and the consolidation of its operations in the priority market of Mexico.   LatAm as a region offers many opportunities for innovation.…

Canada Biosimilar uptake initiatives are gaining traction across Canada and have already been implemented in several provinces. Dara Jospé and Lina Bensaidane of Fasken examine the impact of these policies on patients, prescribers, and pharmacists thus far, and the implications should non-medical biosimilar switching become a nationwide norm.   In the…

China Despite the impact of the COVID-19 pandemic and the vagaries of the country’s restrictive ‘dynamic zero COVID’ policy, the Chinese pharmaceutical industry is expected to continue its remarkable trajectory up to 2025 with annual growth of 9.4 percent. Read on for five key trends to watch out for in the…

China The top 10 Chinese pharma companies for 2022, ranked by sales value and based on data from the latest Forbes Global 2000 ranking. Big conglomerates like Sinopharm, Shanghai Pharmaceuticals, and Jointown dominate the list, while other national champions in the midst of expanding their innovation efforts like Jiangsu Hengrui and…

Global The FDA’s recent accelerated approval for Bluebird Bio’s gene therapy Skysona and its US list price of USD three million per treatment has reignited the global debate around drug pricing. Bluebird execs are keen to emphasise how life-changing such treatments are for a small number of patients; Skysona is indicated…

Spain Over the course of 2022, PharmaBoardroom spoke to over 50 leading stakeholders in the Spanish healthcare and life sciences, from top Spanish scientists to regional ministers of health, multinational affiliate managers, and the heads of some of the country’s leading domestic firms. These interviewees’ insights are catalogued in the downloadable…

Egypt MSD’s managing director for Egypt, Libya, Sudan and Yemen, Hazem Abdel Samie, shares his perspective on recent changes within the American multinational and explains why Egypt’s move from a predominantly out-of-pocket market to a public system will open up many new opportunities. He also offers his view on the possibility…

Singapore On World Heart Day 2022 Iris Zemzoum of Novartis Asia Pacific, Middle East & Africa (APMA) outlines the devastating impact of cardiovascular disease (CVD) as well as Novartis’ multipronged approach to overcoming healthcare disparities across a diverse region that is home to half the world’s population. Speaking at the outset…

Netherlands The latest news from the Dutch pharma, biotech and healthcare industries, including the bullish comments of Argenx CEO Tim Van Hauwermeiren following the successful launch of its Vyvgart product; cancer diagnostic firm Agendia’s decision to withdraw from a US IPO; and the latest on cross-border travel and vaccines in the…

Egypt Bayer’s Hatem Ismail introduces the company’s important work to help Egypt meet its ambitious Vision 2030 transformation goals; its significant footprint in the country across innovative pharmaceuticals, OTC drugs, and crop science products; and his bold ambitions for the affiliate’s future growth.   Bayer Egypt probably has one of the…

Italy Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in the country’s National Recovery and Resilience Plan and a priority within its healthcare modernisation plans.   Novel solutions came out…